Compare GLP-1 Medications
These side-by-side comparisons show what each GLP-1 medication is FDA-approved for, how the doses step up, which pens it comes in and its most common side effects, taken directly from each product's current US prescribing information.
Last reviewed against FDA labeling.
Most-asked comparisons
Ozempic vs Mounjaro
Ozempic (semaglutide) vs Mounjaro (tirzepatide): FDA-approved uses, dose steps, pens and side effects from each label. Reviewed against FDA labeling.
Ozempic vs Wegovy
Ozempic and Wegovy are both semaglutide. Compare their FDA-approved uses, dose steps up to 2 mg vs 2.4–7.2 mg, pens and tablets, from each label.
Wegovy vs Zepbound
Wegovy (semaglutide) vs Zepbound (tirzepatide): approved uses, dosing, label trial results and the SURMOUNT-5 head-to-head trial. Sourced and dated.
Mounjaro vs Zepbound
Mounjaro and Zepbound are both tirzepatide from Eli Lilly. See how their FDA-approved uses, dose steps, pens and storage compare, from each label.
Ozempic vs Saxenda
Ozempic (semaglutide, once weekly) vs Saxenda (liraglutide, once daily): different medicines and approved uses. Label-sourced doses, pens and side effects.
Ozempic vs Trulicity
Ozempic (semaglutide) vs Trulicity (dulaglutide): two once-weekly GLP-1 shots for type 2 diabetes. Approved uses, doses and pens from each FDA label.
At a glance
| Brand | Active ingredient | How often | Weight management approval | Maker |
|---|---|---|---|---|
| Ozempic | semaglutide | Once weekly | No (type 2 diabetes) | Novo Nordisk |
| Wegovy | semaglutide | Once weekly (injection) | Yes | Novo Nordisk |
| Saxenda | liraglutide | Once daily | Yes | Novo Nordisk |
| Mounjaro | tirzepatide | Once weekly | No (type 2 diabetes) | Eli Lilly |
| Zepbound | tirzepatide | Once weekly | Yes | Eli Lilly |
| Trulicity | dulaglutide | Once weekly | No (type 2 diabetes) | Eli Lilly |
Source: each product's FDA prescribing information on DailyMed, linked from every comparison page.
Other pairings
Side-by-side label facts for other combinations. These use the same FDA-sourced data but don't have a written review.
Comparisons we retired
We removed comparisons for these products because they no longer have current US prescribing information. If you still use one, ask your prescriber about alternatives.
- Byetta (exenatide): Listed as discontinued in Drugs@FDA. Source (checked September 24, 2026)
- Bydureon and Bydureon BCise (exenatide extended-release): Both listed as discontinued in Drugs@FDA. Source (checked September 24, 2026)
- Lyxumia (lixisenatide): Lyxumia is the European brand name. The European Commission withdrew its EU marketing authorisation on December 18, 2025, at Sanofi’s request. In the US the stand-alone brand was Adlyxin, which has no current label on DailyMed; the only lixisenatide product with a current DailyMed label is Soliqua 100/33 (insulin glargine and lixisenatide). Source, No current stand-alone lixisenatide (Adlyxin) label (checked September 24, 2026)
Medical disclaimer: This page is general information, not medical advice, diagnosis or treatment, and it doesn't cover every use, dose, warning or side effect. Always follow the advice of your doctor, pharmacist or other prescriber and read the Medication Guide that comes with your medicine. If you think you are having a medical emergency, call your local emergency number. ShotWise is a tracking app and does not prescribe, sell or recommend any medication.
Track Your GLP-1 Shots with ShotWise
ShotWise logs each dose and injection site, sends dose reminders on the schedule you set and charts your weight over time. It doesn't give medical advice; your prescriber decides your dose.
Download ShotWise